Log in
NASDAQ:GNFT

Genfit Stock Forecast, Price & News

$5.60
+0.09 (+1.63 %)
(As of 12/1/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.31
Now: $5.60▼
$5.60
50-Day Range
$3.63
MA: $4.49▼
$5.54
52-Week Range
$3.63
Now: $5.60▼
$22.48
Volume14,856 shs
Average Volume86,605 shs
Market Capitalization$211.86 million
P/E RatioN/A
Dividend YieldN/A
Beta0.73
Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions for metabolic, inflammatory, autoimmune, and fibrotic diseases affecting primarily the liver and gastroenterology. The company's lead products include Elafibranor, which is in pivotal Phase III clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), as well as completed Phase II clinical trial to treat patients with primary biliary cholangitis; and Nitazoxanide that is in Phase II proof-of-concept clinical trial for the treatment of NASH-induced significant or severe fibrosis. It is also developing in-vitro diagnostic tests for the identification of patients with NASH; NIS4 for identifying patients with NASH and fibrosis; and TGFTX1 preclinical program for treating psoriasis or respiratory conditions, such as neutrophilic asthma, chronic obstructive pulmonary disease (COPD), and the asthma-COPD overlap syndrome. Genfit SA was founded in 1999 and is headquartered in Loos, France.

Beat the Market (BTM) Rank™

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.26 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNFT
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.genfit.com
Phone33-3-20-16-40-00
Employees203

Debt

Debt-to-Equity Ratio5.74
Current Ratio5.71
Quick Ratio5.71

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$45.88 million
Price / Sales4.62
Cash FlowN/A
Price / Cash FlowN/A
Book Value$2.49 per share
Price / Book2.25

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares37,833,000
Market Cap$211.86 million
Next Earnings DateN/A
OptionableNot Optionable
$5.60
+0.09 (+1.63 %)
(As of 12/1/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive GNFT News and Ratings via Email

Sign-up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Genfit (NASDAQ:GNFT) Frequently Asked Questions

How has Genfit's stock been impacted by Coronavirus (COVID-19)?

Genfit's stock was trading at $14.23 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GNFT shares have decreased by 60.6% and is now trading at $5.60.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Genfit?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genfit in the last year. There are currently 3 sell ratings, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Genfit or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Genfit?

Wall Street analysts have given Genfit a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Genfit wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What price target have analysts set for GNFT?

10 brokerages have issued 12 month price objectives for Genfit's stock. Their forecasts range from $7.00 to $174.00. On average, they anticipate Genfit's share price to reach $44.60 in the next twelve months. This suggests a possible upside of 696.4% from the stock's current price.
View analysts' price targets for Genfit.

Are investors shorting Genfit?

Genfit saw a increase in short interest in November. As of November 15th, there was short interest totaling 69,500 shares, an increase of 22.6% from the October 31st total of 56,700 shares. Based on an average trading volume of 106,400 shares, the short-interest ratio is currently 0.7 days.
View Genfit's Short Interest.

Who are some of Genfit's key competitors?

Some companies that are related to Genfit include Vaxart (VXRT), Taysha Gene Therapies (TSHA), Cardiff Oncology (CRDF), Titan Pharmaceuticals (TTNP), Agenus (AGEN), Poseida Therapeutics (PSTX), Osiris Therapeutics (OSIR), Sutro Biopharma (STRO), Aptose Biosciences (APTO), Adaptimmune Therapeutics (ADAP), Precision BioSciences (DTIL), Aligos Therapeutics (ALGS), Aerie Pharmaceuticals (AERI), Fusion Pharmaceuticals (FUSN) and Oyster Point Pharma (OYST).
View all competitors.

What other stocks do shareholders of Genfit own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Intercept Pharmaceuticals (ICPT), InterDigital (IDCC), STAG Industrial (STAG), Gilead Sciences (GILD), Occidental Petroleum (OXY), Vaxart (VXRT), Exxon Mobil (XOM), Zynerba Pharmaceuticals (ZYNE), Aimmune Therapeutics (AIMT) and Amarin (AMRN).

Who are Genfit's key executives?

Genfit's management team includes the following people:
  • Mr. Jean-François Mouney, Co-Founder & Chairman (Age 65)
  • Mr. M. Pascal Prigent, Chief Exec. Officer (Age 52)
  • Prof. Bart Staels, Co-Founder & Chairman of the Scientific Advisory Board (Age 57)
  • Ms. Nathalie Huitorel, Exec. VP and Chief Financial & Admin. Officer (Age 59)
  • Dr. Dean W. Hum, Chief Operating Officer (Age 58)
  • Ms. Naomi Eichenbaum, VP of Investor Relations
  • Mr. Laurent Lannoo, Corp. Sec. & Director of Legal Affairs (Age 50)
  • Mr. Jean-Christophe Marcoux, Chief Strategy Officer (Age 43)
  • Dr. Carol L. Addy M.D., Chief Medical Officer (Age 60)
  • Mr. Suneil Hosmane Ph.D., Head of Global Diagnostics (Age 38)

When did Genfit IPO?

(GNFT) raised $132 million in an initial public offering (IPO) on Wednesday, March 27th 2019. The company issued 5,000,000 shares at $26.33 per share. SVB Leerink and Barclays served as the underwriters for the IPO and Bryan, Garnier, Natixis, Roth Capital Partners and H.C. Wainwright & Co. were co-managers.

What is Genfit's stock symbol?

Genfit trades on the NASDAQ under the ticker symbol "GNFT."

Who are Genfit's major shareholders?

Genfit's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (0.11%), OLD Mission Capital LLC (0.11%) and Morgan Stanley (0.08%).

Which institutional investors are selling Genfit stock?

GNFT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., and Morgan Stanley.

Which institutional investors are buying Genfit stock?

GNFT stock was bought by a variety of institutional investors in the last quarter, including OLD Mission Capital LLC.

How do I buy shares of Genfit?

Shares of GNFT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Genfit's stock price today?

One share of GNFT stock can currently be purchased for approximately $5.60.

How big of a company is Genfit?

Genfit has a market capitalization of $211.86 million and generates $45.88 million in revenue each year. The company earns $-72,960,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. Genfit employs 203 workers across the globe.

What is Genfit's official website?

The official website for Genfit is www.genfit.com.

How can I contact Genfit?

Genfit's mailing address is PARC 885 AVENUE EUGENE AVINEE, LOOS I0, 59120. The company can be reached via phone at 33-3-20-16-40-00 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.